PRESS RELEASES

Date	Title
Jun 29, 2023	Ardelyx, Inc. Reports Employment Inducement Grants
Jun 5, 2023	Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
May 31, 2023	Ardelyx to Present at the Jefferies 2023 Healthcare Conference
May 23, 2023	Ardelyx, Inc. Reports Employment Inducement Grants
May 17, 2023	Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
May 15, 2023	Ardelyx, Inc. Reports Employment Inducement Grants
May 9, 2023	Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
May 3, 2023	Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
May 1, 2023	Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
Apr 26, 2023	Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 617.675.ARDX (2739)

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com